Doing deals in a time of coronavirus: Biotech CEO Bill Haney says 'you focus on the things that make a difference'
Bill Haney counts his blessings where he finds them these days.
As CEO of two biotechs — Skyhawk and Dragonfly — he’s had a front row seat to watch the “dramatic” impact the pandemic can have on operations. But he’s quick to offer thanks that no one in his two companies — or their families — have yet to be infected.
“We know this challenge is coming for people we care about, and we’re concerned about that,” says Haney.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 83,000+ biopharma pros reading Endpoints daily — and it's free.